Trial reportPsychopharmacology2006
Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial.
Trial report in Psychopharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Donepezil for dementia due to Alzheimer's disease.The Cochrane database of systematic reviews · 2018Pooled it
- Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease.Scientific reports · 2017Trial
- Longitudinal changes of fractional anisotropy in Alzheimer's disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study.European archives of psychiatry and clinical neuroscience · 2012Trial
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Cholinergic modulation of sensory perception and plasticity.Neuroscience and biobehavioral reviews · 2023Review
- Comparison of [Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
- Generation of synthetic PET images of synaptic density and amyloid fromMedical physics · 2021Article
- Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.JAMA neurology · 2018Article
- Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.) · 2016Article
- Cognitive Correlates of Basal Forebrain Atrophy and Associated Cortical Hypometabolism in Mild Cognitive Impairment.Cerebral cortex (New York, N.Y. : 1991) · 2016Article
- PET Evidence of the Effect of Donepezil on Cognitive Performance in an Animal Model of Chemobrain.BioMed research international · 2016Article
- Use of biomarkers in clinical trials of Alzheimer disease: from concept to application.Molecular diagnosis & therapy · 2011Article
- Cholinergic modulation of cognition: insights from human pharmacological functional neuroimaging.Progress in neurobiology · 2011Review
- Using biomarkers to improve detection of Alzheimer's disease.Neurodegenerative disease management · 2011Article
- Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.Nature reviews. Drug discovery · 2010Review
- The use of PET in Alzheimer disease.Nature reviews. Neurology · 2010Review
- The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES).The journal of nutrition, health & aging · 2009Review
- Biological markers for early detection and pharmacological treatment of Alzheimer's disease.Dialogues in clinical neuroscience · 2009Review
- [Neurobiological early diagnosis of Alzheimer's disease].Der Nervenarzt · 2007Review
- Improvement of episodic contextual memory by S 18986 in middle-aged mice: comparison with donepezil.Psychopharmacology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleCholinergic enhancement is among the best established treatments of Alzheimer's disease (AD). The cognitive effects of treatment are thought to be mediated by improvement of neuronal transmission. Positron emission tomography using 18F-fluorodeoxyglucose (FDG-PET) by measuring cortical metabolic response to activation assesses integrity of neuronal transmission in vivo.
objectiveTo determine the effects of treatment with donepezil, a centrally selective acetylcholinesterase inhibitor, on cortical metabolism in AD using 18FDG-PET.
methodsWe enrolled 23 patients, 18 of which completed the study, with mild to moderate probable AD (mini-mental status exam scores of 15-28, inclusive) in a double-blind cross over trial of 8 weeks donepezil compared to 8 weeks placebo with repeated double 18FDG-PET examinations during passive audio-visual stimulation. Effects of treatment on cortical metabolic response to stimulation were determined with a linear model on a voxel level using Statistical Parametric Mapping (SPM 99, Wellcome Department of Imaging Neuroscience, London).
resultsEffects of treatment on cognitive measures were not different between donepezil and placebo. During passive audio-visual stimulation, patients showed activation in posterior visual and auditory areas and decreased activation in frontal cortex and basal ganglia. Resting state metabolism was increased with donepezil in left prefrontal cortex and decreased in right hippocampus. Cortical response to activation was increased in right hippocampus with donepezil compared to placebo.
conclusionDonepezil treatment shows a spatially limited functional effect on right hippocampus and left prefrontal cortical metabolism, independently of clinical response to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.